cero.bio (CERO): תחזית צמיחת רווח נקי למניה לשנה הבאה

CERo Therapeutics (CERO) dominates the cell therapy segment through unique phagocytosis methods and robust patent protection. Analyst 12-month EPS growth targets reflect expectation dynamics, where the value of 75.70 corresponds to the current metric. Growth is supported by an elite group of scientists utilizing an academic approach and generous RSUs, as well as strict compliance with environmental regulations regarding biohazardous waste disposal.
פילוחי נתונים אנליטיים מרוכזים עבור CERo Therapeutics Holdings, Inc. (CERO)

This indicator aggregates daily changes in analysts' consensus earnings per share (EPS) forecasts, filtering out short-term volatility to identify a sustainable fundamental trend. The price action of the target net EPS growth rate allows for a real-time assessment of CERo Therapeutics (CERO) management's ability to meet clinical trial deadlines, separating genuine market expectations from speculative noise following the IPO.